These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2109665)

  • 1. Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion.
    Schneck DW; Callaghan JT; Bergstrom RF; Obermeyer BD; Offen WW
    Clin Pharmacol Ther; 1990 Apr; 47(4):499-503. PubMed ID: 2109665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of oral nizatidine.
    Vargas R; Ryan J; McMahon FG; Regel G; Offen WW; Matsumoto C
    J Clin Pharmacol; 1988 Jan; 28(1):71-5. PubMed ID: 2895125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous nizatidine kinetics and acid suppression.
    Callaghan JT; Bergstrom RF; Obermeyer BD; King EP; Offen WW
    Clin Pharmacol Ther; 1985 Feb; 37(2):162-5. PubMed ID: 2857117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin.
    Hammond JB; Offen WW
    Am J Gastroenterol; 1988 Jan; 83(1):32-6. PubMed ID: 2892392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of an oral evening dose of nizatidine on nocturnal and peptone-stimulated gastric acid and gastrin secretion.
    Kovacs TO; Van Deventer GM; Maxwell V; Sytnik B; Walsh JH
    Scand J Gastroenterol Suppl; 1987; 136():41-6. PubMed ID: 2892254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nizatidine suppression of basal gastric acid output: a comparison of two intravenous dosage regimens.
    Danziger L; Furmaga KM; Rodvold KA; Bombeck CT; Fischer JH
    J Clin Pharmacol; 1989 Oct; 29(10):946-52. PubMed ID: 2574190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of pH dataloggers for pharmacologic studies.
    Chiverton SG; Burget DW; Hunt RH
    Scand J Gastroenterol; 1989 Oct; 24(8):975-81. PubMed ID: 2512632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 21:00 h.
    Lanzon-Miller S; Pounder RE; Chronos NA; Raymond F; Hamilton MR; Dalgleish D
    Gut; 1988 Oct; 29(10):1364-9. PubMed ID: 2904394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibition of 24-hour acidity by nizatidine].
    Dammann HG; Dreyer M; Gottlieb WR; Wolf N; Müller P; Simon B
    Fortschr Med; 1989 May; 107(14):321-4. PubMed ID: 2568971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
    Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
    Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs.
    Lin TM; Evans DC; Warrick MW; Pioch RP
    J Pharmacol Exp Ther; 1986 Nov; 239(2):406-10. PubMed ID: 2877081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acid inhibitory characteristics of nizatidine in man: an overview.
    Parente F; Bianchi Porro G
    Scand J Gastroenterol Suppl; 1994; 206():3-7. PubMed ID: 7863250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oral nizatidine on preoperative gastric fluid pH and volume in children.
    Mikawa K; Nishina K; Maekawa N; Takao Y; Obara H
    Br J Anaesth; 1994 Nov; 73(5):600-4. PubMed ID: 7826786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early evening nizatidine intake with a meal optimizes the antisecretory effect.
    Duroux P; Emde C; Bauerfeind P; Biollaz J; Armstrong D; Blum AL
    Aliment Pharmacol Ther; 1993 Feb; 7(1):47-54. PubMed ID: 8439637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.
    Savarino V; Mela GS; Zentilin P; Scalabrini P; Bonifacino G; Gambaro P; Celle G
    Digestion; 1989; 42(1):1-6. PubMed ID: 2568299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacokinetic profile of nizatidine in man.
    Callaghan JT; Bergstrom RF; Rubin A; Chernish S; Crabtree R; Knadler MP; Obermeyer B; Offen WW; Schneck DW; Aronoff G
    Scand J Gastroenterol Suppl; 1987; 136():9-17. PubMed ID: 2892261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of gastric acid rebound after stopping a successful short-term course of nizatidine in duodenal ulcer patients.
    Savarino V; Mela GS; Zentilin P; Sumberaz A; Bonifacino G; Celle G
    Am J Gastroenterol; 1991 Mar; 86(3):281-4. PubMed ID: 1671805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of interaction between nizatidine and warfarin during chronic administration.
    Cournot A; Berlin I; Sallord JC; Singlas E
    J Clin Pharmacol; 1988 Dec; 28(12):1120-2. PubMed ID: 2907521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of various dose regimens of famotidine on basal nocturnal and meal-stimulated gastric secretion.
    Ryan JR; Chremos AN; Vargas R; Mantell G; Johnson CL; McMahon FG
    Clin Pharmacol Ther; 1987 Aug; 42(2):225-31. PubMed ID: 2886245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nizatidine versus ranitidine in the treatment of acute duodenal ulcer. Comparison of 300 mg nizatidine and 300 mg ranitidine in a single evening dose].
    Arnold R; Beckenbach P; Bock H; Bormann R; Daake H; Dammann HG; Du Bosque G; Fürer M; Geiter B; Hebbeln H
    Fortschr Med; 1989 Jul; 107(21):467-70. PubMed ID: 2570012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.